Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Vaccine. 2011 Oct 6;29(43):7514-22. doi: 10.1016/j.vaccine.2011.03.083. Epub 2011 Apr 16.

A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.

Author information

  • 1Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Oxford, OX3 7LJ, UK. david.porter@paediatrics.ox.ac.uk

Abstract

We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum. Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria sporozoite challenge. The vaccines were safe but interferon-γ ELISPOT responses were low compared to other poxvirus vectors, despite targeting multiple antigens. There was no vaccine efficacy as measured by delay in time to parasitaemia. A number of possible explanations are discussed, including the very large insert size of the polyprotein transgene.

Copyright © 2011 Elsevier Ltd. All rights reserved.

PMID:
21501642
[PubMed - indexed for MEDLINE]
PMCID:
PMC3195259
Free PMC Article

Images from this publication.See all images (8)Free text

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk